The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Subscribe To Our Newsletter & Stay Updated
